Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
symbol | company | %chng | last | %short | avg$volume | |
---|---|---|---|---|---|---|
BIIB | Biogen, Inc. | 0.55% | 293.85 | 1.4% | $595.18m | |
AMGN | Amgen, Inc. | 0.85% | 235.99 | 1.3% | $497.59m | |
GILD | Gilead Sciences, Inc. | 0.72% | 67.63 | 1.0% | $369.81m | |
REGN | Regeneron Pharmaceuticals, Inc. | -0.37% | 372.16 | 2.6% | $302.06m | |
VRTX | Vertex Pharmaceuticals, Inc. | 0.25% | 220.55 | 1.9% | $275.13m | |
CLVS | Clovis Oncology, Inc. | 14.59% | 13.43 | 14.7% | $241.85m | |
ILMN | Illumina, Inc. | 0.44% | 321.99 | 3.5% | $235.54m | |
ARWR | Arrowhead Pharmaceuticals, Inc. | -1.32% | 67.32 | 11.4% | $205.58m | |
ALXN | Alexion Pharmaceuticals, Inc. | 2.71% | 112.47 | 2.0% | $202.78m | |
A | Agilent Technologies, Inc. | 1.73% | 84.86 | 1.6% | $165.50m | |
EXAS | EXACT Sciences Corp. | 0.29% | 85.42 | 24.0% | $161.05m | |
GBT | Global Blood Therapeutics, Inc. | -1.99% | 76.89 | 6.0% | $140.66m | |
BLUE | bluebird bio, Inc. | -3.36% | 84.05 | 14.2% | $136.75m | |
BOLD | Audentes Therapeutics, Inc. | -0.12% | 59.37 | 1.4% | $134.85m | |
SGEN | Seattle Genetics, Inc. | 0.83% | 112.26 | 6.1% | $128.97m |
Company Profile
Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.